BO
Blue Owl Capital Holdings LP
13F filer · CIK 0001858703Reported Aug 11, 2026
Net buyer this quarter
13F portfolio value$665MU.S. long equity reported on 13F
Positions7116 new · 10 closed
Net flow last quarter+$271MBuys minus sells
Top 10 positions weight78.5%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 11, 202671 positions | |||||
| $239M | 35.97% | Not reported | New | Q2 2026 | |
| $99M | 14.89% | 5.74% | -2.9% | Q1 2026 | |
| $28M | 4.22% | 2.39% | -19.4% | Q4 2023 | |
| $27.9M | 4.21% | 8.82% | +28.7% | Q4 2023 | |
| $26.6M | 4.01% | 4.34% | Not reported | Q1 2025 | |
| $26.2M | 3.94% | 1.61% | -27.4% | Q1 2026 | |
| $24M | 3.62% | 0.02% | New | Q2 2026 | |
| $22.2M | 3.35% | 0.41% | Not reported | Q4 2022 | |
| $14.7M | 2.22% | 2.23% | New | Q2 2026 | |
| $14.2M | 2.14% | 0.01% | +137.2% | Q4 2021 | |
| $11.2M | 1.68% | 3.64% | +3.3% | Q1 2025 | |
| $10.9M | 1.64% | 0.90% | -16.4% | Q1 2025 | |
| $9.74M | 1.47% | 4.11% | +277.6% | Q4 2023 | |
| $9.09M | 1.37% | 0.72% | +11.7% | Q1 2026 | |
| $8.48M | 1.28% | 3.54% | New | Q2 2026 | |
| $7.94M | 1.19% | 2.01% | +23.2% | Q4 2023 | |
| $7.35M | 1.11% | 3.24% | Not reported | Q1 2025 | |
| $6.82M | 1.03% | 0.09% | Not reported | Q1 2026 | |
| $6.37M | 0.96% | 0.33% | Not reported | Q1 2025 | |
| $6.1M | 0.92% | 0.19% | -39.7% | Q4 2023 | |
| $5.54M | 0.83% | 0.25% | +16.0% | Q1 2025 | |
| $5.41M | 0.81% | 8.14% | -4.3% | Q3 2025 | |
| $4.78M | 0.72% | 0.23% | New | Q2 2026 | |
| $4.51M | 0.68% | 0.61% | -20.1% | Q1 2026 | |
| $4.33M | 0.65% | 0.39% | +166.7% | Q1 2026 | |
| $4.3M | 0.65% | 2.41% | +49.3% | Q1 2026 | |
| $3.92M | 0.59% | 0.75% | -30.1% | Q1 2024 | |
| $3.22M | 0.48% | 0.05% | +23.9% | Q4 2021 | |
| $2.39M | 0.36% | 0.50% | +80.0% | Q1 2026 | |
| $2.23M | 0.34% | 0.70% | -60.1% | Q1 2025 | |
| $2.22M | 0.33% | 0.44% | Not reported | Q2 2025 | |
| $1.84M | 0.28% | 0.13% | New | Q2 2026 | |
| $1.63M | 0.24% | 3.19% | -42.4% | Q2 2024 | |
| $1.35M | 0.20% | 0.84% | -11.8% | Q1 2026 | |
| $815K | 0.12% | 3.32% | Not reported | Q1 2025 | |
| $785K | 0.12% | 0.58% | Not reported | Q3 2022 | |
| $396K | 0.06% | 0.12% | New | Q2 2026 | |
| $385K | 0.06% | 1.56% | Not reported | Q2 2025 | |
| $381K | 0.06% | Not reported | -16.2% | Q1 2025 | |
| $214K | 0.03% | Not reported | Not reported | Q1 2025 | |
| $204K | 0.03% | Not reported | -12.8% | Q1 2025 | |
| $176K | 0.03% | 0.00% | Not reported | Q1 2026 | |
| $148K | 0.02% | Not reported | Not reported | Q4 2023 | |
| $131K | 0.02% | 0.00% | Not reported | Q2 2024 | |
| $103K | 0.02% | Not reported | New | Q2 2026 | |
| $102K | 0.02% | 0.00% | Not reported | Q1 2026 | |
| $84K | 0.01% | 0.00% | Not reported | Q1 2026 | |
| $71K | 0.01% | 0.00% | New | Q2 2026 | |
| $68.4K | 0.01% | Not reported | Not reported | Q1 2025 | |
| $62.9K | 0.01% | 0.33% | New | Q2 2026 | |
| Q1 2026Reported May 14, 202665 positions | |||||
| $56.6M | 15.20% | 5.92% | New | Q1 2026 | |
| $32M | 8.61% | 6.85% | Not reported | Q4 2023 | |
| $30.1M | 8.08% | 6.59% | Not reported | Q4 2023 | |
| $27.3M | 7.33% | 4.34% | Not reported | Q1 2025 | |
| $27.1M | 7.29% | 3.11% | Not reported | Q4 2023 | |
| $22.6M | 6.08% | 0.41% | Not reported | Q4 2022 | |
| $20.5M | 5.49% | 2.23% | New | Q1 2026 | |
| $15.6M | 4.18% | 1.63% | Not reported | Q4 2023 | |
| $13.3M | 3.58% | 5.54% | Not reported | Q2 2024 | |
| $13M | 3.49% | 3.53% | Not reported | Q1 2025 | |
| $11.8M | 3.16% | 1.09% | Not reported | Q1 2025 | |
| $7.97M | 2.14% | 0.65% | New | Q1 2026 | |
| $6.45M | 1.73% | 3.25% | Not reported | Q1 2025 | |
| $6.34M | 1.70% | 0.31% | Not reported | Q4 2023 | |
| $5.59M | 1.50% | 1.08% | Not reported | Q1 2024 | |
| $5.34M | 1.44% | 0.09% | New | Q1 2026 | |
| $4.99M | 1.34% | 1.03% | New | Q1 2026 | |
| $4.8M | 1.29% | 8.58% | Not reported | Q3 2025 | |
| $4.78M | 1.28% | 1.65% | Not reported | Q1 2025 | |
| $4.64M | 1.25% | 1.62% | New | Q1 2026 | |
| $4.37M | 1.18% | 1.87% | Not reported | Q1 2025 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $4.33M | 1.16% | 0.42% | Not reported | Q3 2025 |
| $4.23M | 1.14% | 1.14% | Not reported | Q4 2023 | |
| $3.9M | 1.05% | 0.22% | Not reported | Q1 2025 | |
| $3.74M | 1.01% | 4.80% | Not reported | Q4 2023 | |
| $2.73M | 0.73% | 0.04% | Not reported | Q4 2021 | |
| $2.59M | 0.70% | 0.58% | Not reported | Q3 2022 | |
| $2.3M | 0.62% | 0.28% | New | Q1 2026 | |
| $2.28M | 0.61% | 0.00% | Not reported | Q4 2021 | |
| $1.9M | 0.51% | 0.14% | New | Q1 2026 | |
| $1.74M | 0.47% | 1.09% | Not reported | Q4 2023 | |
| $1.31M | 0.35% | 0.96% | New | Q1 2026 | |
| $1.29M | 0.35% | Not reported | Not reported | Q4 2023 | |
| $1.18M | 0.32% | 0.00% | Not reported | Q1 2025 | |
| $1.13M | 0.30% | 1.70% | Not reported | Q2 2025 | |
| $867K | 0.23% | Not reported | Not reported | Q1 2025 | |
| $721K | 0.19% | 3.32% | Not reported | Q1 2025 | |
| $525K | 0.14% | Not reported | Not reported | Q1 2025 | |
| $417K | 0.11% | Not reported | Not reported | Q1 2025 | |
| $363K | 0.10% | 0.00% | Not reported | Q1 2025 | |
| $202K | 0.05% | Not reported | Not reported | Q1 2025 | |
| $186K | 0.05% | 0.00% | New | Q1 2026 | |
| $146K | 0.04% | 0.77% | Not reported | Q1 2025 | |
| $103K | 0.03% | 0.00% | New | Q1 2026 | |
| $94.8K | 0.03% | 1.88% | New | Q1 2026 | |
| $84.2K | 0.02% | 0.00% | New | Q1 2026 | |
| $74.2K | 0.02% | Not reported | Not reported | Q1 2025 | |
| $63K | 0.02% | 1.77% | Not reported | Q1 2025 | |
| GGOCOGoHealth, Inc. | $61.6K | 0.02% | 4077.00% | Not reported | Q4 2021 |
| $41.5K | 0.01% | 0.17% | Not reported | Q1 2025 | |
| Q3 2025Reported Nov 12, 202569 positions | |||||
| $42.7M | 13.24% | 6.26% | -23.5% | Q1 2025 | |
| $26.1M | 8.11% | 0.40% | Not reported | Q4 2022 | |
| $22.4M | 6.95% | 6.40% | -12.1% | Q4 2023 | |
| $18.9M | 5.87% | 6.84% | +18.8% | Q4 2023 | |
| $18.3M | 5.67% | 0.91% | Not reported | Q1 2024 | |
| $15.3M | 4.74% | 4.07% | +18.2% | Q1 2025 | |
| $15M | 4.64% | 0.14% | Not reported | Q1 2025 | |
| $14.9M | 4.62% | 4.25% | +5.2% | Q4 2023 | |
| $12.7M | 3.94% | 0.44% | +65.5% | Q4 2023 | |
| $12.5M | 3.87% | 2.88% | Not reported | Q1 2025 | |
| $9.11M | 2.83% | 4.33% | Not reported | Q4 2023 | |
| $9.07M | 2.82% | 1.46% | Not reported | Q4 2023 | |
| $7.42M | 2.30% | 0.01% | +151.0% | Q4 2021 | |
| $7.3M | 2.27% | 2.73% | Not reported | Q1 2025 | |
| $7.18M | 2.23% | 8.06% | Not reported | Q2 2024 | |
| $6.99M | 2.17% | 1.03% | +35.9% | Q1 2024 | |
| $6.76M | 2.10% | 0.29% | -16.4% | Q4 2023 | |
| RTRPTXRepare Therapeutics Inc. | $6.06M | 1.88% | 8.01% | Not reported | Q4 2023 |
| $5.97M | 1.85% | 0.86% | -24.0% | Q1 2025 | |
| $5.23M | 1.62% | 0.53% | -34.7% | Q1 2025 | |
| $5.03M | 1.56% | 1.12% | -16.0% | Q2 2025 | |
| $4.41M | 1.37% | 13.45% | New | Q3 2025 | |
| $4.39M | 1.36% | 4.83% | Not reported | Q4 2023 | |
| CPCNTACentessa Pharmaceuticals PLC | $4.11M | 1.28% | 0.13% | -48.7% | Q1 2025 |
| $3.85M | 1.20% | 2.12% | New | Q3 2025 | |
| $3.83M | 1.19% | 0.13% | -70.0% | Q4 2023 | |
| $3.47M | 1.08% | 0.63% | +163.1% | Q1 2025 | |
| $2.93M | 0.91% | 0.65% | Not reported | Q3 2022 | |
| $2.78M | 0.86% | Not reported | Not reported | Q2 2022 | |
| $2.58M | 0.80% | 0.16% | Not reported | Q2 2024 | |
| $2.54M | 0.79% | 1.64% | -26.3% | Q1 2025 | |
| AACLXArcellx, Inc. | $2.2M | 0.68% | 0.05% | Not reported | Q4 2022 |
| KPKALVKalVista Pharmaceuticals, Inc. | $1.52M | 0.47% | 0.25% | New | Q3 2025 |
| $1.45M | 0.45% | 1.78% | Not reported | Q2 2025 | |
| $1.01M | 0.31% | Not reported | Not reported | Q1 2025 | |
| $1M | 0.31% | 0.11% | -85.3% | Q1 2025 | |
| $978K | 0.30% | 0.00% | Not reported | Q1 2025 | |
| $557K | 0.17% | Not reported | Not reported | Q1 2023 | |
| $543K | 0.17% | 2.60% | Not reported | Q1 2025 | |
| $500K | 0.16% | 0.01% | -56.4% | Q2 2025 | |
| $495K | 0.15% | 3.32% | Not reported | Q1 2025 | |
| $470K | 0.15% | Not reported | -38.6% | Q1 2025 | |
| $454K | 0.14% | 0.94% | Not reported | Q1 2025 | |
| $270K | 0.08% | 0.00% | Not reported | Q1 2025 | |
| $211K | 0.07% | Not reported | New | Q3 2025 | |
| $166K | 0.05% | 1.59% | Not reported | Q1 2025 | |
| $144K | 0.04% | Not reported | Not reported | Q1 2025 | |
| $80.1K | 0.02% | Not reported | Not reported | Q2 2025 | |
| $70K | 0.02% | Not reported | Not reported | Q1 2025 | |
| $59K | 0.02% | Not reported | Not reported | Q1 2025 | |
| Q2 2025Reported Aug 11, 202568 positions | |||||
| $65.4M | 21.11% | 8.15% | Not reported | Q1 2025 | |
| $29.3M | 9.46% | 0.40% | Not reported | Q4 2022 | |
| $18M | 5.80% | 4.04% | -2.1% | Q4 2023 | |
| $17.2M | 5.56% | 0.90% | Not reported | Q1 2024 | |
| TBTRMLTourmaline Bio, Inc. | $15.9M | 5.15% | 3.88% | -3.9% | Q4 2023 |
| $14.2M | 4.60% | 7.70% | +3.1% | Q4 2023 | |
| $13.6M | 4.38% | 7.30% | +13.7% | Q4 2023 | |
| $11.8M | 3.80% | 2.80% | -21.8% | Q1 2025 | |
| $10.1M | 3.27% | 4.33% | Not reported | Q4 2023 | |
| $9.28M | 3.00% | 0.26% | +66.6% | Q4 2023 | |
| $8.22M | 2.65% | 3.44% | -22.7% | Q1 2025 | |
| $7.33M | 2.37% | 2.50% | -8.9% | Q1 2025 | |
| $6.74M | 2.17% | 1.87% | -12.3% | Q4 2023 | |
| $6.47M | 2.09% | 0.35% | -12.8% | Q4 2023 | |
| $5.29M | 1.71% | 0.82% | -29.5% | Q1 2025 | |
| $5.09M | 1.64% | Not reported | New | Q2 2025 | |
| $4.85M | 1.57% | 8.26% | +0.5% | Q2 2024 | |
| RTRPTXRepare Therapeutics Inc. | $4.79M | 1.54% | 8.02% | Not reported | Q4 2023 |
| $4.55M | 1.47% | 0.51% | +62.9% | Q4 2023 | |
| CPCNTACentessa Pharmaceuticals PLC | $4.34M | 1.40% | 0.25% | +5.0% | Q1 2025 |
| $4.17M | 1.35% | 0.73% | -61.6% | Q1 2025 | |
| $3.6M | 1.16% | 2.22% | -26.9% | Q1 2025 | |
| $3.44M | 1.11% | 4.84% | Not reported | Q4 2023 | |
| $3.05M | 0.98% | 0.93% | Not reported | Q1 2024 | |
| $2.82M | 0.91% | 1.13% | -10.7% | Q1 2025 | |
| $2.64M | 0.85% | 0.04% | Not reported | Q4 2021 | |
| $2.56M | 0.82% | 0.00% | Not reported | Q4 2021 | |
| $2.34M | 0.76% | 2.24% | New | Q2 2025 | |
| $1.97M | 0.63% | 0.65% | Not reported | Q3 2022 | |
| $1.92M | 0.62% | 1.84% | New | Q2 2025 | |
| VPVRNAVerona Pharma plc | $1.74M | 0.56% | 0.00% | Not reported | Q1 2025 |
| $1.71M | 0.55% | 1.23% | New | Q2 2025 | |
| $1.56M | 0.50% | 1.33% | New | Q2 2025 | |
| ATAPGEApogee Therapeutics, Inc. | $1.52M | 0.49% | 0.06% | New | Q2 2025 |
| $1.22M | 0.39% | 0.03% | New | Q2 2025 | |
| $970K | 0.31% | 0.00% | Not reported | Q1 2025 | |
| $848K | 0.27% | 4.90% | Not reported | Q1 2025 | |
| $644K | 0.21% | 0.25% | -79.8% | Q1 2025 | |
| $559K | 0.18% | 0.09% | Not reported | Q1 2025 | |
| $418K | 0.13% | 0.97% | Not reported | Q1 2025 | |
| $381K | 0.12% | Not reported | -21.0% | Q1 2025 | |
| $294K | 0.09% | 1.59% | Not reported | Q1 2025 | |
| $289K | 0.09% | 0.00% | Not reported | Q1 2025 | |
| $277K | 0.09% | Not reported | -28.7% | Q1 2025 | |
| $202K | 0.07% | Not reported | Not reported | Q1 2025 | |
| $165K | 0.05% | 2.69% | Not reported | Q1 2025 | |
| $103K | 0.03% | Not reported | Not reported | Q1 2025 | |
| $69.8K | 0.02% | Not reported | Not reported | Q1 2025 | |
| $52K | 0.02% | Not reported | Not reported | Q1 2025 | |
| $50.2K | 0.02% | Not reported | Not reported | Q1 2025 | |
Premium opens every quarter this fund has filed